University of Arkansas
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Arkansas sits in the top decile of US sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count).
University of Arkansas: 318 sponsored US clinical trials, 37 recruiting.
University of Arkansas sponsors 318 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 202 completed. 17 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 15 trials.
Top-decile sponsor footprint
University of Arkansas ranks in the top decile of sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
202 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
318 total, page 7 of 7
Effects of Exercise in Combination With Epoetin Alfa
NCT00577096
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
NCT00083915
Regulation of Cerebral Blood Flow in Very Low Birth Weight Infants
NCT00579943
Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone
NCT00218608
Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery
NCT00569855
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally
NCT00083538
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
NCT00083707
Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation
NCT00575744
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
NCT00083382
An Open Protocol for the Compassionate Use of Thalidomide
NCT00081757
D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma
NCT00083876
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
NCT00083694
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
NCT00083551
DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse
NCT00083681
Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy
NCT00083902
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
NCT00083408
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
NCT00083577
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
NCT00002652
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 40 |
| Phase 2 | 62 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the University of Arkansas pipeline
37 recruiting of 318 indexed (12% open); 202 completed (64%).
Phase mix: 17 late (III/IV) vs 102 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Arkansas: open-pipeline peers nationwide
Peers matched on 318 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 318 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
- Allergan · 314 trials · 0% recruiting
- Celgene · 308 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Jazz Pharmaceuticals · 12% recruiting · 128 trials
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
Related
What to do with this University of Arkansas page
318 registered trials is a research-attention snapshot, not an endorsement of University of Arkansas or any single study.
- 37 of University of Arkansas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition University of Arkansas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Arkansas pipeline card: 318 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.